Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 172Terminated 55Unknown 48Recruiting 48Active not recruiting 28Withdrawn 23Not yet recruiting 15Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Head & Neck 1Breast 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 4Docetaxel 3pembrolizumab 2Nivolumab 2Etoposide 2Carboplatin 2osimertinib 1icotinib 1famitinib 1durvalumab 1decitabine and cedazuridine drug combination 1dabrafenib 1cemiplimab 1alirocumab 1aldesleukin 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Radionuclide Imaging 1Radiation 1Prednisone 1Positron-Emission Tomography 1Platinum 1Pemetrexed 1Panitumumab 1Paclitaxel 1Monatide (IMS 3015) 1Methods 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Radiotherapy × Thoracic × Clear all
NCT04929041 2026-05-13

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

National Cancer Institute (NCI)

Phase 2/3 Suspended
427 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡